Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

WCLC 2026 | Class 3 BRAF alterations predict poor immunotherapy outcomes in NSCLC

Alessandro Di Federico, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses a retrospective study on class 2 and class 3 BRAF alterations in non-small cell lung cancer (NSCLC), which found that class 3 alterations were associated with a higher tumor mutational burden and poorer outcomes with immunotherapy. Mutations in genes such as STK11, CDKN1, and SMARCA4 were more frequent in tumors with class 3 alterations and were consistently associated with worse overall survival, suggesting that these tumors may have limited responsiveness to immunotherapy. This interview took place at the IASLC 2026 World Conference on Lung Cancer congress in Seoul, Republic of Korea.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.